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Abstract. Background/Aim: The focal adhesion kinase (FAK)/SRC phosphorylation 
cascade and its downstream target paxillin have been implicated in malignant 
transformation, tumor growth and progression, together with metastasis. The present 
study aimed to evaluate the clinical significance of concomitant FAK/SRC and p-
paxillin expression in mobile tongue squamous cell carcinoma (SCC). Materials and 
Methods: FAK, SRC and phospho-paxillin expression in 48 mobile tongue SCC tissue 
samples was assessed immunohistochemically and analyzed with respect to 
clinicopathological characteristics and patient survival. Results: Concomitant high 
FAK/SRC expression was significantly associated with high grade of tumor 
differentiation (p=0.048) and longer disease-free patient survival (log-rank test, 
p=0.019). High p-paxillin expression was significantly associated with greater depth of 
invasion (p=0.002), lymph node metastasis (p=0.048) and poorer disease-free patient 
survival (log-rank test, p=0.021; Cox-regression analysis, p=0.031). Conclusion: The 
present study provides evidence that FAK/SRC and paxillin play a role in the 
pathophysiological aspects of mobile tongue SCC and could constitute therapeutic 
targets.  
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Focal adhesion kinase (FAK) and proto-oncogene tyrosine protein kinase SRC are 
ubiquitously expressed non-receptor tyrosine kinases (1, 2). They are reciprocally 
activated by phosphorylation (3, 4) and the FAK/SRC dual kinase complex initiates 
multiple phosphorylation cascades, regulating several cellular functions, including 
integrin-mediated cell adhesion and migration, angiogenesis, cell cycle, cell 
proliferation and apoptosis (5). A prominent phosphorylation substrate of the FAK/SRC 
kinase complex is paxillin (6, 7), which interacts with several proteins coordinating 
changes in the actin cytoskeleton associated with cell motility and cell adhesion.  
 The involvement of FAK/SRC in cellular pathways that regulate cell survival, 
growth, invasion and motility (8, 9) suggests that they contribute to the development 
of cancer and are putative drug targets for treatment (10-13). Similarly, paxillin has 
been implicated in tumor progression, angiogenesis and metastasis, either as a 
downstream target of FAK/SRC or in its own right (14-17). Clinical studies have 
revealed that FAK, SRC and paxillin expression are significantly correlated with 
clinicopathological parameters and patient survival in many cancer types (18-24).  
 Mobile tongue squamous cell carcinoma (SCC) is the most common 
malignancy diagnosed within the oral cavity (25). Despite advanced therapeutic 
strategies, the 5-year survival rate has not been considerably improved, mainly due to 
lymph node metastasis at diagnosis (26, 27). Therefore there is an urgent need to 
establish reliable prognostic markers in mobile tongue SCC. In light of the above 
considerations, the present study aimed to assess concomitant FAK/SRC and 
phospho (p)-paxillin expression levels immunohistochemically in 48 mobile tongue 
SCC samples, in association with clinicopathological parameters and patient survival. 
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Materials and Methods 
The medical records and archival histopathological material of the 48 patients with 
mobile tongue SCC included in this study were described in detail previously (28). 
Clinical and histopathological parameters were assessed according to standard 
criteria as described elsewhere (28). Immunostaining for FAK, SRC and p-paxillin was 
performed as described elsewhere (28-30), using primary antibodies detecting FAK, 
c-SRC and p-paxillin (Tyr118), respectively (all from Santa Cruz Biotechnology, Santa 
Cruz, CA, USA). Appropriate negative controls were performed by omitting the primary 
antibody or substituting it with an irrelevant anti-serum. As positive controls, 
pancreatic, thyroid and endometrial cancer tissue sections with known increased FAK 
and SRC immunoreactivity (29-31) and colon cancer tissue sections with known 
increased p-paxillin immunoreactivity (unpublished data) were used. The 
immunoreactivity was scored according to the percentage of FAK, SRC and p-paxillin 
positive tumor cells as 0: negative staining; 0-4% of cells positive; 1: 5-24% of cells 
positive; 2: 25-49% of cells positive; 3: 50-100% of cells positive, and its intensity as 
0: negative staining; 1: mild staining; 2: intermediate staining; 3: intense staining. 
Expression was classified as low, if the total score was 0 or 2, and high, if the total 
score was ≥3 (28, 32, 33). Concomitant high FAK/SRC expression was defined as 
cases presenting simultaneously high FAK and SRC expression, whereas 
concomitant low FAK/SRC expression was defined as cases presenting low 
expression in either FAK or SRC or both proteins. Statistical analysis was performed 
as described previously (28): chi-square test was used to assess the associations of 
concomitant FAK/Src and p-paxillin expression with clinicopathological variables, 
Kaplan-Meier survival curves were compared by the log rank test and a Cox 
proportional-hazard regression model was developed to evaluate the association 
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between the potential prognostic marker and overall and disease-free survival. A p-
value less than 0.05 was considered the limit of statistical significance. 
 
Results 
All 48 samples of mobile tongue SCC were found to stain positively for FAK, SRC and 
p-paxillin and representative immunostaining results are shown in Figure 1. 
Concomitant high FAK/SRC expression was positively associated with histological 
grade of tumor differentiation (Table I, p=0.048), whereas no associations with patient 
age and gender or any other clinicopathological parameters examined were recorded. 
High p-paxillin expression was significantly associated with greater depth of invasion 
and lymph node metastasis (Table I, p=0.002 and p=0.048, respectively). 
 Kaplan–Meier survival curves indicated that patients with mobile tongue SCC 
with concomitant high FAK/SRC expression presented non-significantly longer (Figure 
2A, log-rank test, p=0.057) and those with high p-paxillin expression shorter (Figure 
2B, log-rank test, p=0.226) overall survival times compared to those with low 
expression. Longer overall patient survival was also significantly correlated with 
female gender and lesser depth of invasion (Table II, p=0.010 and p=0.047, 
respectively), while a trend for correlation of better survival with dense stromal 
inflammatory reaction and well-defined tumor shape was noted (p=0.050 and p=0.069, 
respectively). 
 Univariate analysis also showed that patients with mobile tongue SCC with 
concomitant high FAK/SRC expression presented significantly longer disease-free 
survival times compared to those with low expression (Figure 2C, log-rank test, 
p=0.019). Moreover, longer disease-free survival was significantly correlated with 
female gender, well-defined tumor shape and high histological grade of tumor 
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differentiation (Table II, p=0.007, p=0.034 and p=0.040, respectively), while a trend for 
correlation between disease-free survival and dense stromal inflammatory reaction 
was also recorded (p=0.054). However, concomitant FAK/SRC expression, as well as 
patient gender, and tumor grade and shape, did not remain significant in multivariate 
analysis concerning disease-free survival (Table III). 
 In contrast, Kaplan–Meier survival curves indicated that patients with mobile 
tongue SCC with high p-paxillin expression presented significantly shorter disease-
free survival times compared to those with low expression (Figure 2D, log-rank test, 
p=0.021). In multivariate analysis, patient gender and p-paxillin expression were 
identified as independent factors associated with disease-free patient survival (Cox-
regression analysis, p=0.033 and p=0.031, respectively). 
 
Discussion 
The role of the FAK/SRC/paxillin axis in human malignancy is well established (8-24) 
but its role in mobile tongue SCC is still being investigated. As an extension to our 
previous investigations (28), the present study evaluated the associations between 
concomitant FAK/SRC expression and clinicopathological parameters, together with 
overall and disease-free patient survival. We confirmed the correlation of concomitant 
FAK/SRC expression with high tumor differentiation grade, observed by Theocharis et 
al. (2012) for FAK and SRC separately, and illustrated the association of concomitant 
FAK/SRC expression with longer disease-free patient survival, noted previously for 
SRC only (28). Additionally, we investigated the possibility that p-paxillin, a 
downstream target of the FAK/SRC phosphorylation cascade, would show similar 
correlations. However we demonstrated the opposite effect suggesting that these 
proteins do not operate together in this context. More specifically, high p-paxillin 
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expression was significantly associated with greater tumor depth of invasion and 
presence of lymph node metastasis, while patients with mobile tongue SCC with high 
p-paxillin expression presented significantly shorter disease-free survival times 
compared to those with low expression. Thus p-paxillin expression was identified as 
an independent factor in disease-free patient survival. The present observations 
support the implication of FAK/SRC and p-paxillin signalling in disease progression 
and recurrence. However, the opposite associations noted between concomitant 
FAK/SRC, and p-paxillin expression with clinicopathological parameters and patient 
survival suggest that FAK/SRC and paxillin mediate their effects independently. High 
p-paxillin expression in mobile tongue SSC is probably controlled by other signalling 
pathways and leads to poor prognosis in contrast to the positive prognosis associated 
with high FAK/SRC expression, attesting to the complexity of molecular interactions in 
clinical samples. It should be noted that paxillin also has an upstream regulatory role 
on the FAK/SRC complex by mediating its localization at focal adhesions (3, 34, 35). 
Interestingly, Conway et al. (36) reported that paxillin over expression represses FAK 
phosphorylation in SCC25 tongue squamous cancer cells.  
 In support of the above findings, Jiang et al. documented a significant increase 
in FAK protein expression levels in well-differentiated tongue tumors as compared to 
poorly differentiated types (37). Additionally, increased paxillin expression levels were 
associated with lymph node metastasis and shorter overall survival times in tongue 
SCC (38). Similar correlations between high paxillin expression and advanced 
clinicopathological parameters together with poor prognosis have been noted in 
salivary adenoid cystic carcinoma (39) and laryngeal SCC (40). In general, FAK and 
SRC constitute promising targets for anticancer therapy (11, 13). Taking into 
consideration the results of the present study, the FAK/SRC pathway could be 
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targeted indirectly in order to increase and not inhibit signalling. Although no paxillin 
inhibitors are available to date (41), this molecule could also have potential therapeutic 
utility in mobile tongue SCC. 
 The present study provides evidence that the FAK/SRC/paxillin axis may play 
a role in the pathophysiological aspects of mobile tongue SCC, being associated with 
crucial clinicopathological parameters for patient management and prognosis. 
However the current investigation only concerned a limited number of patients and 
relatively few clinical events, limiting our ability to draw more precise conclusions 
Further investigations should utilize a larger patient cohort to assess FAK and SRC 
activity. Both would be monitored by quantifying their activated-phosphorylated forms 
together with investigations of other downstream targets, apart from paxillin, in order 
to establish their clinical significance and therapeutic potential in mobile tongue SCC. 
Additionally, future research effort should focus on the assessment of the exact role 
of paxillin in the pathophysiological aspects that affect disease progression and 
prognosis in mobile tongue SCC. 
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Figure 1. Representative immunostaining results for focal adhesion kinase (A), proto-
oncogene tyrosine protein kinase SRC (B) and phospho-paxillin (C) protein expression 
in tumor cells of mobile tongue squamous cell carcinoma. Streptavidin-biotin-
peroxidase, 3,3-diaminobenzidine (DAB) chromogen, Harris hematoxylin counterstain 
(original magnification ×400). 
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Figure 2.  Kaplan–Meier survival analysis of overall (A, B) and  disease-free (C, D) 
survival stratified according to concomitant focal adhesion kinase (FAK)/proto-
oncogene tyrosine protein kinase SRC (A, C) and phospho-paxillin (B,  D) protein 
expression in patients with mobile tongue squamous cell carcinoma. 
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Table I: Associations of concomitant focal adhesion kinase (FAK)/proto-oncogene 
tyrosine protein kinase SRC and phospho-paxillin expression with clinicopathological 
parameters in 48 patients with mobile tongue squamous cell carcinoma. 
Clinicopathological 
characteristic 
Concomitant FAK/SRC expression p-Paxillin expression 
Low, n (%)  High, n (%) p-Value Low, n (%) High, n (%) p-Value 
N=48 33 (68.8) 15 (31.2)  33 (68.8) 15 (31.2)  
Age mean±SD   0.636   0.636 
≤62.2±14.6 years 20 (41.7) 8 (16.7)  20 (41.7) 8 (16.7)  
>62.2±14.6 years 13 (27.1) 7 (14.6)  13 (27.1) 7 (14.6)  
Gender   0.259   0.459 
Male  19 (39.6) 6 (12.5)  16 (33.3) 9 (18.8)  
Female 14 (29.2) 9 (18.7)  17 (35.4) 6 (12.5)  
Histopathological 
grade 
  0.048   0.369 
I 22 (45.8) 14 (29.1)  26 (54.2) 10 (20.8)  
II 11 (22.9) 1 (2.1)  7 (14.6) 5 (10.4)  
Stromal inflammatory 
reaction 
  0.457   0.175 
Mild/moderate 10 (20.8) 3 (6.3)  7 (14.6) 6 (12.5)  
Dense 23 (47.9) 12 (25.0)  26 (54.2) 9 (18.8)  
Muscular invasion   0.869   0.473 
Yes 28 (58.3) 13 (27.1)  29 (60.4) 12 (25.0)  
No 5 (10.4) 2 (4.1)  4 (8.3) 3 (6.3)  
Shape   0.175   0.457 
Diffuse 26 (54.3) 9 (18.7)  23 (47.9) 12 (25.0)  
Well-defined 7 (14.6) 6 (12.5)  10 (20.8) 3 (6.3)  
Vascular invasion   0.502   0.151 
Yes 6 (12.5) 4 (8.3)  5 (10.4) 5 (10.4)  
No 27 (56.3) 11 (22.9)  28 (58.3) 10 (20.8)  
Perineural invasion   0.269   0.636 
Yes 12 (25.0) 8 (16.6)  13 (27.1) 7 (14.6)  
No 21 (43.8) 7 (14.6)  20 (41.7) 8 (16.7)  
Depth of invasion   0.839   0.002 
I+II 21 (43.8) 10 (20.8)  26 (54.2) 5 (10.4)  
III 12 (25.0) 5 (10.4)  7 (14.6) 10 (20.8)  
Lymph node 
metastasis 
  1.000   0.048 
Yes 11 (22.9) 5 (10.4)  8 (16.7) 8 (16.7)  
No 22 (45.8) 10 (20.8)  25 (52.1) 7 (14.6)  
  18 
Mitotic index   0.613   0.459 
≤Median  15 (31.3) 8 (16.7)  17 (35.4) 6 (12.5)  
>Median 18 (37.5) 7 (14.6)  16 (33.3) 9 (18.8)  
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Table II. Association of clinicopathological parameters, concomitant focal adhesion 
kinase (FAK)/proto-oncogene tyrosine protein kinase SRC and phospho-paxillin 
expression with patient survival: Univariate analysis. 
Clinicopathological parameters Mean OS (95% CI), 
months 
p-Value Mean DFS (95% 
CI), months 
p-Value 
Age <62.2 years 65.2 (50.9-79.5) 0.381 63.0 (48.8-77.2) 0.607 
≥62.2 years 87.2 (66.4-108.0)  78.3 (57.3-99.3)  
Gender Male 55.9 (41.1-70.7) 0.010 51.7 (37.6-65.9) 0.007 
Female 100.5 (84.5-116.4)  95.4 (78.0-112.8)  
Histopathological 
grade 
I 85.5 (69.4-101.7) 0.179 82.8 (66.8-98.9) 0.040 
II 46.2 (35.0-54.4)  41.7 (31.1-52.4)  
Stromal 
inflammatory 
reaction  
Mild, 
moderate 
53.9 (37.0-70.8) 0.050 50.4 (33.9-66.9) 0.054 
Dense 90.3 (74.2-106.4)  84.1 (67.5-100.7)  
Muscular 
invasion  
Yes 55.0 (38.7-68.8) 0.554 49.4 (35.5-63.3) 0.995 
No 78.9 (63.4-94.3)  74.7 (59.5-89.9)  
Shape Diffuse 63.3 (50.6-76.0) 0.069 58.3 (46.1-70.5) 0.034 
Well-defined 105.8 (87.6-124.0)  105.8 (87.6-124.0)  
Vascular invasion  Yes 57.4 (35.9-78.8) 0.418 57.4 (35.9-78.8) 0.645 
No 83.7 (67.7-99.7)  76.7 (60.8-92.6)  
Perineural 
invasion 
Yes 72.3 (52.2-87.4) 0.533 72.3 (57.2-87.4) 0.185 
No 74.8 (54.2-95.4)  64.8 (45.8-83.7)  
Depth of invasion I+II 77.8 (66.3-89.3) 0.047 71.1 (59.0-83.1) 0.177 
III 63.5 (39.2-87.7)  63.5 (39.2-87.7)  
Lymph node 
metastasis 
Yes 63.2 (45.9-80.5) 0.595 59.8 (42.5-77.0) 0.631 
No 82.7 (64.7-100.6)  76.8 (59.3-94.4)  
Mitotic index ≤Median 82.2 (62.7-101.6) 0.977 73.8 (54.3-93.2) 0.831 
>Median 67.7 (53.4-81.9)  64.7 (50.1-79.3)  
Concomitant 
FAK/SRC 
expression 
Low 59.5 (47.2-71.8) 0.057 54.4 (42.7-66.1) 0.019 
High 100.5 (80.9-120.0)  100.5 (80.9-120.0)  
p-Paxillin 
expression 
Low 74.1 (62.1-86.1) 0.226 74.1 (62.1-86.1) 0.021 
High 69.9 (43.8-96.0)  53.4 (31.8-75.1)  
OS: Overall survival; DFS: disease-free survival; CI: confidence interval. 
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Table III. Association of clinicopathological parameters and concomitant focal 
adhesion kinase (FAK)/proto-oncogene tyrosine protein kinase SRC and phospho-
paxillin expression with disease-free patient survival: Multivariate analysis. 
Variable 
Disease free-survival 
Concomitant FAK/SRC p-Paxillin 
HR (95% CI) p-Value HR (95% CI) p-Value 
Gender: Female vs.  
male 
0.284 (0.075-1.080) 0.065 0.282 (0.088-0.902) 0.033 
Tumor grade: II vs. I 1.988 (0.590-6.701) 0.268 3.014 (0.972-9.347) 0.056 
Tumor shape: Well-
defined vs. diffuse 
0.203 (0.026-1.600) 0.130 0.148 (0.019-1.178) 0.071 
Protein expression: High 
vs. low 
0.381 (0.077-1.879) 0.236 3.148 (1.110-8.928) 0.031 
HR: Hazard ratio; CI: confidence interval.  
